BCG vaccination-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4+IL-17+TNF+IL-2+ T cells

Vaccine

Volumn 33, Issue 1, 2015, Pages 85-91

  Cruz, Andrea ^a,b   Torrado, Egídio ^a,b   Carmona, Jenny ^a,b   Fraga, Alexandra G ^a,b   Costa, Patrício ^a,b   Rodrigues, Fernando ^a,b   Appelberg, Rui ^c   Correia Neves, Margarida ^a,b   Cooper, Andrea M ^d   Saraiva, Margarida ^a,b   Pedrosa, Jorge ^a,b   Castro, António G ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d TRUDEAU INSTITUTE   (United States)

Author keywords

BCG vaccination; Effector CD4+ T cells; Memory CD4+ T cells; Multifunctional CD4+ T cells; Tuberculosis

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL IMMUNITY; BACTERIOSTASIS; BCG VACCINATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; INFECTION CONTROL; LUNG TUBERCULOSIS; MEMORY T LYMPHOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; TIME; TUBERCULOSIS; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; SECRETION (PROCESS); T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; IMMUNOLOGIC MEMORY; INTERLEUKIN-17; INTERLEUKIN-2; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919360521     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.013     Document Type: Article

References (49)

1. WHO Global tuberculosis control 2011, WHO.
2. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
4. Kaufmann S.H. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010, 33:567-577.
5. Lambert P.H., Hawkridge T., Hanekom W.A. New vaccines against tuberculosis. Clin Chest Med 2009, 30:811-826.
6. Pitt J.M., Blankley S., McShane H., O'Garra A. Vaccination against tuberculosis: how can we better BCG. Microb Pathog 2013, 58:2-16.
7. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
8. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
9. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
10. lo T cells in mycobacterial infection. Eur J Immunol 2012, 42:3267-3279.
11. Torrado E., Robinson R.T., Cooper A.M. Cellular response to mycobacteria: balancing protection and pathology. Trends Immunol 2011, 32:66-72.
12. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178:2243-2247.
13. Green A.M., Difazio R., Flynn J.L. IFN-gamma from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol 2013, 190:270-277.
14. Goldsack L., Kirman J.R. Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis. Tuberculosis (Edinburgh) 2007, 87:465-473.
15. + Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun 2009, 77:622-631.
16. Leal I.S., Smedegard B., Andersen P., Appelberg R. Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation. Immunology 2001, 104:157-161.
17. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182:8047-8055.
18. + T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 2009, 183:2659-2668.
19. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40:279-290.
20. + T cells in adults. Am J Respir Crit Care Med 2010, 181:1407-1417.
21. Torrado E., Cooper A.M. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010, 21:455-462.
22. + induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204:1573-1584.
23. Orme I.M. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987, 138:293-298.
24. Orme I.M. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J Immunol 1988, 140:3589-3593.
25. Cruz A., Fraga A.G., Fountain J.J., Rangel-Moreno J., Torrado E., Saraiva M., et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010, 207:1609-1616.
26. Cruz A., Khader S.A., Torrado E., Fraga A., Pearl J.E., Pedrosa J., et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4T cells during mycobacterial infection. J Immunol 2006, 177:1416-1420.
27. Teixeira-Coelho M., Cruz A., Carmona J., Sousa C., Ramos-Pereira D., Saraiva A.L., et al. TLR2 deficiency by compromising p19 (IL-23) expression limits Th17 cell responses to Mycobacterium tuberculosis. Int Immunol 2011, 23:89-96.
28. Fraga A.G., Cruz A., Martins T.G., Torrado E., Saraiva M., Pereira D.R., et al. Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 2011, 79:421-430.
29. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
30. + effector memory T cells. J Immunol 2008, 180:7948-7957.
31. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
32. Hirahara K., Poholek A., Vahedi G., Laurence A., Kanno Y., Milner J.D., et al. Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J Allergy Clin Immunol 2013, 131:1276-1287.
33. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007, 37:3089-3100.
34. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
35. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H.L., Amara R.R. Multiple-cytokine-producing antiviral CD4T cells are functionally superior to single-cytokine-producing cells. J Virol 2007, 81:8468-8476.
36. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006, 203:1249-1258.
37. Vilaplana C., Prats C., Marzo E., Barril C., Vegue M., Diaz J., et al. To achieve an earlier IFN-gamma response is not sufficient to control Mycobacterium tuberculosis infection in mice. PLoS One 2014, 9:e100830.
38. Gallegos A.M., van Heijst J.W., Samstein M., Su X., Pamer E.G., Glickman M.S. A gamma interferon independent mechanism of CD4T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011, 7:e1002052.
39. Torrado E., Cooper A.M. What do we really know about how CD4T cells control Mycobacterium tuberculosis?. PLoS Pathog 2011, 7:e1002196.
40. Kaufmann S.H., McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005, 11:S33-S44.
41. Walzl G., Ronacher K., Hanekom W., Scriba T.J., Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
42. Lindenstrom T., Knudsen N.P., Agger E.M., Andersen P. Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J Immunol 2013, 190:6311-6319.
43. Kryczek I., Zhao E., Liu Y., Wang Y., Vatan L., Szeliga W., et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med 2011, 3:104ra0.
44. Gopal R., Rangel-Moreno J., Slight S., Lin Y., Nawar H.F., Fallert Junecko B.A., et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol 2013, 6:972-984.
45. Slight S.R., Rangel-Moreno J., Gopal R., Lin Y., Fallert Junecko B.A., Mehra S., et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest 2013, 123:712-726.
46. Lowe D.M., Redford P.S., Wilkinson R.J., O'Garra A., Martineau A.R. Neutrophils in tuberculosis: friend or foe. Trends Immunol 2012, 33:14-25.
47. Yang C.T., Cambier C.J., Davis J.M., Hall C.J., Crosier P.S., Ramakrishnan L. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. Cell Host Microbe 2012, 12:301-312.
48. Sterne J.A., Rodrigues L.C., Guedes I.N. Does the efficacy of BCG decline with time since vaccination. Int J Tuberc Lung Dis 1998, 2:200-207.
49. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.